JPH11511747A - アルコール中毒症を治療するためのピロリジン誘導体の使用 - Google Patents
アルコール中毒症を治療するためのピロリジン誘導体の使用Info
- Publication number
- JPH11511747A JPH11511747A JP8536251A JP53625196A JPH11511747A JP H11511747 A JPH11511747 A JP H11511747A JP 8536251 A JP8536251 A JP 8536251A JP 53625196 A JP53625196 A JP 53625196A JP H11511747 A JPH11511747 A JP H11511747A
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- group
- alkyl
- alk
- tert
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000007848 Alcoholism Diseases 0.000 title claims abstract description 13
- 201000007930 alcohol dependence Diseases 0.000 title claims description 4
- 150000003235 pyrrolidines Chemical class 0.000 title abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 230000035622 drinking Effects 0.000 claims abstract description 7
- 201000010099 disease Diseases 0.000 claims abstract description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 103
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 50
- -1 nitro, amino Chemical group 0.000 claims description 47
- 125000003545 alkoxy group Chemical group 0.000 claims description 35
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 31
- 125000001424 substituent group Chemical group 0.000 claims description 31
- 150000001875 compounds Chemical class 0.000 claims description 29
- 125000005843 halogen group Chemical group 0.000 claims description 25
- 150000003839 salts Chemical group 0.000 claims description 21
- 125000004414 alkyl thio group Chemical group 0.000 claims description 20
- 125000004432 carbon atom Chemical group C* 0.000 claims description 20
- 229910052757 nitrogen Inorganic materials 0.000 claims description 20
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 17
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 16
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 15
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims description 15
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 125000002947 alkylene group Chemical group 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 11
- 239000005711 Benzoic acid Substances 0.000 claims description 10
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 235000010233 benzoic acid Nutrition 0.000 claims description 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 9
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 8
- 125000002252 acyl group Chemical group 0.000 claims description 8
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 8
- 125000005842 heteroatom Chemical group 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 229920006395 saturated elastomer Polymers 0.000 claims description 8
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 7
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims description 5
- 125000001041 indolyl group Chemical group 0.000 claims description 5
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims description 5
- 125000001624 naphthyl group Chemical group 0.000 claims description 5
- 125000004585 polycyclic heterocycle group Chemical group 0.000 claims description 5
- 235000019260 propionic acid Nutrition 0.000 claims description 5
- 125000005493 quinolyl group Chemical group 0.000 claims description 5
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 4
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 4
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 claims description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 4
- 125000005170 cycloalkyloxycarbonyl group Chemical group 0.000 claims description 4
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000004434 sulfur atom Chemical group 0.000 claims description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 3
- 125000004694 alkoxyaminocarbonyl group Chemical group 0.000 claims description 3
- 125000002541 furyl group Chemical group 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 125000002950 monocyclic group Chemical group 0.000 claims description 3
- 125000003367 polycyclic group Chemical group 0.000 claims description 3
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- AQKADTOEOXISQG-UHFFFAOYSA-N 2-(carbamoylamino)-2-phenylpropanoic acid Chemical compound NC(=O)NC(C)(C(O)=O)C1=CC=CC=C1 AQKADTOEOXISQG-UHFFFAOYSA-N 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 125000004666 alkoxyiminoalkyl group Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 claims description 2
- KAKQVSNHTBLJCH-UHFFFAOYSA-N trifluoromethanesulfonimidic acid Chemical compound NS(=O)(=O)C(F)(F)F KAKQVSNHTBLJCH-UHFFFAOYSA-N 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N benzyl-alpha-carboxylic acid Natural products OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 claims 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 150000007945 N-acyl ureas Chemical class 0.000 claims 2
- 229960003424 phenylacetic acid Drugs 0.000 claims 2
- 239000003279 phenylacetic acid Substances 0.000 claims 2
- IPIGNHDAVWQEDN-DIUPPUJESA-N 2-[3-[[2-[(2r,4r)-2-(2-fluorophenyl)-4-[(2-methylpropan-2-yl)oxycarbonyl]-1,3-thiazolidin-3-yl]-2-oxoethyl]carbamoylamino]phenyl]propanoic acid Chemical compound OC(=O)C(C)C1=CC=CC(NC(=O)NCC(=O)N2[C@H](SC[C@H]2C(=O)OC(C)(C)C)C=2C(=CC=CC=2)F)=C1 IPIGNHDAVWQEDN-DIUPPUJESA-N 0.000 claims 1
- HLJVZEVBBYBPTJ-KIYNQFGBSA-N C(C)(=O)N1[C@@H](CCC1C1=CC=CC=C1)C(=O)ONC(=O)N Chemical compound C(C)(=O)N1[C@@H](CCC1C1=CC=CC=C1)C(=O)ONC(=O)N HLJVZEVBBYBPTJ-KIYNQFGBSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 150000003254 radicals Chemical class 0.000 claims 1
- 125000004149 thio group Chemical group *S* 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 20
- 239000000203 mixture Substances 0.000 description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102100025841 Cholecystokinin Human genes 0.000 description 4
- 101800001982 Cholecystokinin Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 229940107137 cholecystokinin Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- WIVRIZOJCNHCPS-UHFFFAOYSA-N 2-(carbamoylamino)benzoic acid Chemical compound NC(=O)NC1=CC=CC=C1C(O)=O WIVRIZOJCNHCPS-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 102100021022 Gastrin Human genes 0.000 description 2
- 108010052343 Gastrins Proteins 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 239000004727 Noryl Substances 0.000 description 2
- 229920001207 Noryl Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 2
- HKIOYBQGHSTUDB-UHFFFAOYSA-N folpet Chemical group C1=CC=C2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C2=C1 HKIOYBQGHSTUDB-UHFFFAOYSA-N 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000003533 narcotic effect Effects 0.000 description 2
- NYAZXHASVIWIRJ-UHFFFAOYSA-N nitridosulfidocarbon(.) Chemical compound [S]C#N NYAZXHASVIWIRJ-UHFFFAOYSA-N 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- XWIJIXWOZCRYEL-UHFFFAOYSA-M potassium;methanesulfonate Chemical compound [K+].CS([O-])(=O)=O XWIJIXWOZCRYEL-UHFFFAOYSA-M 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- XTBYHAYSZTUPOD-UHFFFAOYSA-N trifluoromethylsulfamic acid Chemical class OS(=O)(=O)NC(F)(F)F XTBYHAYSZTUPOD-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical group C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- KGRVJHAUYBGFFP-UHFFFAOYSA-N 2,2'-Methylenebis(4-methyl-6-tert-butylphenol) Chemical compound CC(C)(C)C1=CC(C)=CC(CC=2C(=C(C=C(C)C=2)C(C)(C)C)O)=C1O KGRVJHAUYBGFFP-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282551 Cercopithecus Species 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 241001553014 Myrsine salicina Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- VYEYJCBEXFTGBN-UHFFFAOYSA-N acetic acid;1,3-dimethyl-7h-purine-2,6-dione Chemical compound CC(O)=O.O=C1N(C)C(=O)N(C)C2=C1NC=N2 VYEYJCBEXFTGBN-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Substances OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-M prolinate Chemical compound [O-]C(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-M 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 108700028722 receptor-Ck Proteins 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000005505 thiomorpholino group Chemical group 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 式、 式中、 - Rは、メチレン、エチレン、SO、SO2もしくはCHOH基、または硫黄原 子を表し、R1は、場合によっては一つもしくは多数のアルキル基により置換さ れるピリジル基、場合によっては一つもしくは多数のアルキル基により置換され るフリル基、場合によっては一つもしくは多数のアルキル基により置換されるチ エニル基、場合によっては一つもしくは多数のアルキル基により置換されるキノ リル基、場合によっては一つもしくは多数のアルキル基により置換されるナフチ ル基、場合によっては一つもしくは多数のアルキル基により置換されるインドリ ル基、またはハロゲン原子及びアルキル、アルコキシ、ヒドロキシル、ニトロ、 アミノ、モノアルキルアミノ、ジアルキルアミノ、アルコキシカルボニル、−C O−NR7R8、−NH−CO−CH3、トリフルオロメチルもしくはトリフルオ ロメトキシ基から選択される一つもしくは多数の置換基により場合によっては置 換されるフェニル基を表し、そしてR5は、水素原子を表す、 - あるいは、Rは、メチレン基を表し、R1は、水素原子を表し、そしてR5は、 フェニル基を表す、 - あるいは、Rは、CHR6基を表し、そしてR1及びR5は、各々、水 素原子を表す、のいずれかであり、 - R2は、アルコキシカルボニル、シクロアルキルオキシカルボニル、シクロア ルキルアルキルオキシカルボニル、−CONR9R10、またはアルキル、アルコ キシもしくはヒドロキシル基から選択される一つもしくは多数の置換基により場 合によっては置換されるフェニル基を表し、 - R3は、(ハロゲン原子、並びにアルキル、アルコキシ及びアルキルチオ基か ら選択される一つもしくは多数の置換基により場合によっては置換された)フェ ニル基、ナフチル基、インドリル基、キノリル基、あるいは、ハロゲン原子及び アルキル、アルコキシ、アルキルチオ、トリフルオロメチル、カルボキシル、ア ルコキシカルボニル、ヒドロキシル、ニトロ、アミノ、アシル、シアノ、スルフ ァモイル、カルバモイル、ヒドロキシイミノアルキル、アルコキシイミノアルキ ル、ヒドロキシアミノカルボニル、アルコキシアミノカルボニル、テトラゾール −5−イル、テトラゾール−5−イルアルキル、トリフルオロメチルスルホンア ミド、アルキルスルフィニル、モノ−もしくはポリヒドロキシアルキル、スルホ 、−alk−O−CO−alk、−alk−COOX、−alk−O−alk、 −alk’−COOX、−O−alk−COOX、−CH=CH−COOX、− CO−COOX、塩形態の−alk−SO3H、−CH=CH−alk’、−C (=NOH)−COOX、−S−alk−COOX、−O−CH2−alk’− COOX、−CX=N−O−alk−COOX、−alk−N(OH)−CO− alkまたは2,2’−ジメチル−4,6−ジオキソ−1,3−ジオキサン−5 −イル基から選択される一つもしくは多数の置換基によりフェニル環が場合によ っては置換されるフェニルアミノ基を表し、 - R4は、水素原子またはアルキル基を表し、 - R6は、フェニル基を表し、 - R7は、水素原子、またはアルキル、フェニルアルキル、またはハロゲン原子 並びにアルキル、アルコキシ及びアルキルチオ基から選択される一つもしくは多 数の置換基により場合によっては置換されるフェニル基を表し、 - R8は、アルキル、フェニルアルキル、またはハロゲン原子並びにアルキル、 アルコキシ及びアルキルチオ基から選択される一つもしくは多数の置換基により 場合によっては置換されるフェニル基を表し、そうでなければ、R7及びR8は、 これらが結合する窒素原子と共に、4ないし9個の炭素原子及び一つまたは多数 のヘテロ原子(O、N)を含んでいる、場合によっては一つまたは多数のアルキ ル基により置換される、飽和または不飽和の単または多環式の複素環を形成し、 - R9は、水素原子、またはアルキル、シクロアルキルアルキル、シクロアルキ ル、フェニルアルキル、またはハロゲン原子並びにアルキル、アルコキシ及びア ルキルチオ基から選択される一つもしくは多数の置換基により場合によっては置 換されるフェニル基を表し、 - R10は、アルキル、シクロアルキルアルキル、シクロアルキル、フェニルアル キル、またはハロゲン原子並びにアルキル、アルコキシ及びアルキルチオ基から 選択される一つもしくは多数の置換基により場合によっては置換されるフェニル 基を表し、そうでなければ、R9及びR10は、これらが結合する窒素原子と共に 、4ないし9個の炭素原子及び一つまたは多数のヘテロ原子(O、N、S)を含 んでいる、場合によっては一つまたは多数のアルキル基により置換される、飽和 または不飽和の単ま たは多環式の複素環を形成し、 - Xは、水素原子、またはアルキルもしくはフェニルアルキル基を表し、 - alkは、アルキルまたはアルキレン基を表し、 - alk’は、ヒドロキシアルキル、ヒドロキシアルキレン、アルコキシアルキ ルまたはアルコキシアルキレン基を表し、アルキル、アルキレン及びアルコキシ 基、並びにアルキル、アルキレン及びアルコキシ部分は、1ないし4個の直鎖ま たは分岐鎖の炭素原子を含み、アシル基または部分は、2ないし4個の炭素原子 を含み、そしてシクロアルキル基及び部分は、3ないし6個の炭素原子を含むと 理解される、 の化合物、並びにこれらの塩、並びにこれらが少なくとも一つの不斉中心を含む 場合、これらのラセミ化合物及び鏡像異性体の、慢性アルコール中毒症または飲 酒癖による疾患の治療のために意図された薬剤の調製への使用。 2. Rが、メチレン基、硫黄原子またはSO基を表し、R1が、場合によっ ては置換されたフェニル基を表し、R2が、フェニルまたはアルコキシカルボニ ル基を表し、R4及びR5が、水素原子を表し、そしてR3が、カルボキシル、− alk−COOH、−S−alk−COOH、ヒドロキシアルキル、alk’− COOHまたはalkSO3H基によりフェニル基が置換されるフェニルアミノ 基を表す、塩形態の請求の範囲1に記載の式(I)の化合物の、慢性アルコール 中毒症または飲酒癖による疾患の治療のために意図された薬剤の調製への使用。 3. 以下の化合物、 - tert−ブチル(2RS,5SR)−1−{2−[3−(3−(RS)−1 −ヒドロキシエチル)−フェニル)ウレイド]アセチル}−5 −フェニルプロリネート、 - 2−{3−{3−[2−(2S,5R)−2−tert−ブトキシカルボニル −5−フェニル−1−ピロリジニル)−2−オキソエチル]ウレイド}フェニル }プロピオン酸、 - (2RS,5SR)−{3−{3−[2−(2−tert−ブトキシカルボニ ル−5−フェニル−1−ピロリジニル)−2−オキソエチル]ウレイド}フェニ ルチオ}酢酸、 - (2R,4R)−3−{3−[2−(4−tert−ブトキシカルボニル−( 2−フルオロ−3−チアゾリジニル)−2−オキソエチル]ウレイド}フェニル 酢酸、 - 2−{3−{3−[2−((2R,4R)−4−tert−ブトキシカルボニ ル−2−(2−フルオロフェニル)−3−チアゾリジニル)−2−オキソエチル ]ウレイド}フェニル}プロピオン酸、 - (RS)−1−{3−{3−[2−((2R,4R)−4−tert−ブトキ シカルボニル−2−フェニル−3−チアゾリジニル))−2−オキソエチル]ウ レイド}フェニル}エタンスルホン酸カリウム、 - (RS)−1−{3−{3−[2−((2S,5R)−2−tert−ブトキ シカルボニル−5−フェニル−1−ピロリジニル)−2−オキソエチル]ウレイ ド}フェニル}エタンスルホン酸カリウム、 - (2S,5R)−1−{3−{3−[2−(2−tert−ブトキシカルボニ ル−5−フェニル−1−ピロリジニル)−2−オキソエチル]ウレイド}フェニ ルメタンスルホン酸カリウム、 - (2S,5R)−3−{3−[2−2−tert−ブトキシカルボニル−5− フェニル−1−ピロリジニル)−2−オキソエチル]ウレイド} 安息香酸、 - (2RS,5SR)−3−{3−{2−[2−tert−ブトキシカルボニル −5−(2−フルオロフェニル)−1−ピロリジニル]−2−オキソエチル}ウ レイド}安息香酸、 - (シス)−3−{3−[2−(2,5−ジフェニル−1−ピロリジニル)−2 −オキソエチル]ウレイド}安息香酸、 - (2RS,5SR)−3−{{2−[2−(2−ヒドロキシフェニル)−5− フェニル−1−ピロリジニル]−2−オキソウレイド}フェニル酢酸、 - (2R,4R)−3−{3−[2−(4−tert−ブトキシカルボニル−2 −フェニル−3−チアゾリジニル)−2−オキソエチル]ウレイド}フェニル酢 酸、 - (2R,4R)−3−{3−[2−(4−tert−ブトキシカルボニル−2 −フェニル−3−チアゾリジニル)−2−オキソエチル]ウレイド}安息香酸、 - 2−{3−{3−[2−((1RS,2R,4R)−4−tert−ブトキシ カルボニル−2−(2−フルオロフェニル)−1−オキシド−3−チアゾリジニ ル)−2−オキソエチル}ウレイド}フェニル}プロピオン酸、 - (2R,4R)−3−{3−[2−(4−tert−ブトキシカルボニル−2 −(2,3−ジフルオロフェニル)−3−チアゾリジニル)−2−オキソエチル ]ウレイド}フェニル酢酸、 - tert−ブチル(2RS,5SR)−1−{2−{3−[(E)−3−(1 −(ヒドロキシイミノ)エチル)フェニル]ウレイド}アセチ ル}−5−フェニルプロリネート、 から選択される請求の範囲1に記載の式(I)の化合物、並びにこれらが少なく とも一つの不斉炭素を含む場合、これらのラセミ化合物及び鏡像異性体、並びに これらの塩の、慢性アルコール中毒症または飲酒癖による疾患の治療のために意 図された薬剤の調製への使用。 4. 2−{3−{3−[2−((2R,4R)−4−tert−ブトキシカ ルボニル−2−(2−フルオロフェニル)−3−チアゾリジニル)−2−オキソ エチル]ウレイド}フェニル}プロピオン酸の、慢性アルコール中毒症または飲 酒癖による疾患の治療のために意図された薬剤の調製への使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR95/06530 | 1995-06-01 | ||
FR9506530A FR2734724B1 (fr) | 1995-06-01 | 1995-06-01 | Application de derives de pyrrolidine a la preparation de medicaments destines au traitement de l'alcoolisme |
PCT/FR1996/000801 WO1996038139A1 (fr) | 1995-06-01 | 1996-05-29 | Utilisation de derives de pyrrolidine au traitement de l'alcoolisme |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH11511747A true JPH11511747A (ja) | 1999-10-12 |
Family
ID=9479586
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8536251A Pending JPH11511747A (ja) | 1995-06-01 | 1996-05-29 | アルコール中毒症を治療するためのピロリジン誘導体の使用 |
Country Status (27)
Country | Link |
---|---|
US (1) | US5935980A (ja) |
EP (1) | EP0828486B1 (ja) |
JP (1) | JPH11511747A (ja) |
KR (1) | KR100424997B1 (ja) |
CN (1) | CN1186432A (ja) |
AT (1) | ATE224190T1 (ja) |
AU (1) | AU711625B2 (ja) |
BG (1) | BG63189B1 (ja) |
BR (1) | BR9608633A (ja) |
CA (1) | CA2219455C (ja) |
CZ (1) | CZ289344B6 (ja) |
DE (1) | DE69623767T2 (ja) |
DK (1) | DK0828486T3 (ja) |
EA (1) | EA000722B1 (ja) |
ES (1) | ES2182987T3 (ja) |
FR (1) | FR2734724B1 (ja) |
GE (1) | GEP19991780B (ja) |
HU (1) | HUP9900748A3 (ja) |
IL (1) | IL118491A (ja) |
NO (1) | NO975488L (ja) |
NZ (1) | NZ310488A (ja) |
PT (1) | PT828486E (ja) |
RO (1) | RO117297B1 (ja) |
SK (1) | SK282063B6 (ja) |
UA (1) | UA58492C2 (ja) |
WO (1) | WO1996038139A1 (ja) |
ZA (1) | ZA964270B (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2744361B1 (fr) * | 1996-02-07 | 1998-02-27 | Rhone Poulenc Rorer Sa | Application de derives de pyrrolidine a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif |
FR2744363B1 (fr) * | 1996-02-07 | 1998-02-27 | Rhone Poulenc Rorer Sa | Application de derives de thiazolidine a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif |
FR2744362B1 (fr) * | 1996-02-07 | 1998-02-27 | Rhone Poulenc Rorer Sa | Application de derives de pyrrolidine a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif |
TW442449B (en) | 1996-07-04 | 2001-06-23 | Hoechst Ag | Process for preparing 1,2-dichloroethane by direct chlorination |
WO2002072582A1 (en) | 2001-03-12 | 2002-09-19 | Ortho-Mcneil Pharmaceutical, Inc. | Methods for the synthesis of densely functionalized pyrrolidine template libraries |
US6869335B2 (en) | 2002-07-08 | 2005-03-22 | Micron Technology, Inc. | Retaining rings, planarizing apparatuses including retaining rings, and methods for planarizing micro-device workpieces |
US8247438B2 (en) | 2008-02-27 | 2012-08-21 | Neuropill, Inc. | Methods for treating schizophrenia |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2678938B1 (fr) * | 1991-07-10 | 1993-10-08 | Rhone Poulenc Rorer Sa | Derives de pyrrolidine, leur preparation et les medicaments les contenant. |
GB9203790D0 (en) * | 1992-02-21 | 1992-04-08 | Merck Sharp & Dohme | Therapeutic agents |
FR2700166B1 (fr) * | 1993-01-07 | 1995-02-17 | Rhone Poulenc Rorer Sa | Dérivés de pyrrolidine, leur préparation et les médicaments les contenant. |
-
1995
- 1995-06-01 FR FR9506530A patent/FR2734724B1/fr not_active Expired - Fee Related
-
1996
- 1996-05-27 ZA ZA964270A patent/ZA964270B/xx unknown
- 1996-05-29 BR BR9608633A patent/BR9608633A/pt not_active Application Discontinuation
- 1996-05-29 JP JP8536251A patent/JPH11511747A/ja active Pending
- 1996-05-29 AU AU61290/96A patent/AU711625B2/en not_active Ceased
- 1996-05-29 AT AT96918727T patent/ATE224190T1/de active
- 1996-05-29 CN CN96194338A patent/CN1186432A/zh active Pending
- 1996-05-29 CA CA002219455A patent/CA2219455C/fr not_active Expired - Fee Related
- 1996-05-29 ES ES96918727T patent/ES2182987T3/es not_active Expired - Lifetime
- 1996-05-29 KR KR1019970708333A patent/KR100424997B1/ko not_active IP Right Cessation
- 1996-05-29 EP EP96918727A patent/EP0828486B1/fr not_active Expired - Lifetime
- 1996-05-29 UA UA97115678A patent/UA58492C2/uk unknown
- 1996-05-29 EA EA199700439A patent/EA000722B1/ru not_active IP Right Cessation
- 1996-05-29 SK SK1611-97A patent/SK282063B6/sk not_active IP Right Cessation
- 1996-05-29 PT PT96918727T patent/PT828486E/pt unknown
- 1996-05-29 DK DK96918727T patent/DK0828486T3/da active
- 1996-05-29 GE GEAP19964043A patent/GEP19991780B/en unknown
- 1996-05-29 CZ CZ19973785A patent/CZ289344B6/cs not_active IP Right Cessation
- 1996-05-29 DE DE69623767T patent/DE69623767T2/de not_active Expired - Lifetime
- 1996-05-29 NZ NZ310488A patent/NZ310488A/en not_active IP Right Cessation
- 1996-05-29 WO PCT/FR1996/000801 patent/WO1996038139A1/fr active IP Right Grant
- 1996-05-29 US US08/952,937 patent/US5935980A/en not_active Expired - Lifetime
- 1996-05-29 RO RO97-02202A patent/RO117297B1/ro unknown
- 1996-05-29 HU HU9900748A patent/HUP9900748A3/hu unknown
- 1996-05-30 IL IL11849196A patent/IL118491A/en not_active IP Right Cessation
-
1997
- 1997-11-28 NO NO975488A patent/NO975488L/no unknown
- 1997-12-01 BG BG102087A patent/BG63189B1/bg unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007500219A (ja) | 複素環化合物およびその使用法 | |
EP1328269A2 (fr) | Association d'un antagoniste du recepteur cb1 et de sibutramine, pour le traitement de l'obesite | |
CN101417129A (zh) | 包含α-2-δ配体的药物产品及其用途 | |
KR20010079616A (ko) | 과도한 물질 p에 의해 야기된 문제점을 치료하기 위한약물 제조에 사용되는 아릴(또는헤테로아릴)아졸일카르비놀 유도체의 용도 | |
JP2004518628A (ja) | 窒素含有化合物およびそれらのグリシン輸送阻害薬としての使用法 | |
CA3065318A1 (en) | Methods for treatment of fibrotic diseases | |
JPH11511747A (ja) | アルコール中毒症を治療するためのピロリジン誘導体の使用 | |
EP0785781B1 (en) | Use of indole derivatives for the treatment of dermatological disorders peripheral neuropathied, arthritis, allergic or chronic obstructive airways disease, glaucoma and ocular inflammation | |
RU2396251C2 (ru) | Производные альфа-аминоамидов, применимые в качестве противовоспалительных агентов | |
JP2000504681A (ja) | 薬物乱用の処置を目的とする薬剤の製造へのピロリジン誘導体の利用 | |
JP2002513783A (ja) | 疾患を処置するためのsPLA2阻害性化合物 | |
WO2003047576A1 (en) | Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease | |
WO2005011684A1 (de) | Arzneimittel enthaltend derivate von aryl(oder heteroaryl)azolylcarbinolen | |
TWI325317B (en) | Appetite-stimulating agents and remedies for anorexia | |
JPH09500881A (ja) | 抗精神病剤としての2−(2−ヒドロキシフェニル)−5−(n−フェニルメチル−アミノメチル)−ピロール類 | |
JP2004508312A (ja) | 置換ヒドラジン誘導体 | |
MXPA97008875A (en) | Use of pyrrolidine derivatives in the preparation of medicines intended for the alcohol treatment | |
MXPA00010463A (en) | Spla2 | |
MXPA06002189A (en) | Alpha-aminoamide derivatives useful as anti-inflammatory agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070116 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20061220 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070416 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070605 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20081020 |